tiprankstipranks
CymaBay announces collaboration with Kaken to develop, commercialize Seladelpar
The Fly

CymaBay announces collaboration with Kaken to develop, commercialize Seladelpar

CymaBay Therapeutics announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis. Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market seladelpar in Japan for PBC. Kaken will make an upfront payment to CymaBay of approximately $34M at current exchange rates, with additional potential milestone payments to CymaBay totaling up to approximately $128.4 million at current exchange rates, for the achievement of certain regulatory and sales milestones in addition to 20+% royalties. Kaken will be responsible for development, regulatory approval and commercialization of seladelpar in Japan. There are currently no approved second line treatments for PBC in Japan, representing a significant unmet medical need for PBC patients in Japan.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CBAY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles